Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Pictured: An Eli Lilly Research Laboratories sign/

Cardiovascular disease

Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.

November 19, 2024

2 min read

Tristan Manalac

Self-knowledge, exploration of own soul, psyche, illumination of hidden in shadow.

Radiopharma

Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space

The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.

November 18, 2024

2 min read

Nick Paul Taylor

Creative process. Pop art collage. Female hand typing on retro typewriter isolated over white background. Vintage, retro 80s, 70s style. Bright colors. Copy space for ad, text

Editorial

Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

November 15, 2024

3 min read

Annalee Armstrong

Illustration of hand holding trophy with people coming out of trophy and celebrating

Job Trends

BioSpace Announces 2025 Best Places to Work in Biopharma

BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.

November 12, 2024

6 min read

Angela Gabriel

Editorial

Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work

With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.

November 8, 2024

4 min read

Greg Slabodkin

Check mate. hand of businessman moving chess figure Trendy 3d collage in magazine style. Contemporary art. Modern design

GLP-1

While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week. But Eli Lilly reported slower than expected sales in the third quarter due to wholesaler destocking.

November 7, 2024

3 min read

Annalee Armstrong

Podcast

Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More

In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.

November 6, 2024

1 min read

Heather McKenzie

Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VI

Editorial

Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.

November 1, 2024

3 min read

Greg Slabodkin

Image showing college students in lab looking through microscopes

Career Advice

Breaking Into Biotech: What You Must Know to Enter Industry

Candidates looking to enter biotech should focus on cultivating key skills, thoughtfully crafting their resumes and putting their best, most authentic foot forward in interviews. An internship, co-op or fellowship won’t hurt, either.

October 31, 2024

6 min read

Angela Gabriel

JOBS